Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan A Randomized, Double-Blind, Multicenter Study

被引:16
|
作者
Hong, Bum-Kee [2 ]
Park, Chang Gyu [3 ]
Kim, Ki Sik [4 ]
Yoon, Myeong Ho [5 ]
Yoon, Ho Joong [6 ]
Yoon, Jeong Han [7 ]
Yang, Joo Young [8 ]
Choi, Young Jin [9 ]
Cho, Seung Yun [1 ]
机构
[1] Yonsei Univ, Coll Med, Cardiovasc Hosp, Div Cardiol, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Ctr Heart, Seoul, South Korea
[3] Korea Univ, Guro Hosp, Div Cardiol, Seoul, South Korea
[4] Daegu Catholic Univ, Med Ctr, Div Cardiol, Taegu, South Korea
[5] Ajou Univ, Med Ctr, Div Cardiol, Suwon, South Korea
[6] Catholic Univ, Seoul St Mary Hosp, Div Cardiol, Seoul, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Div Cardiol, Songnam, Gyeonggi Do, South Korea
[8] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Cardiol, Ilsan, South Korea
[9] Hallym Univ, Med Ctr, Hanging Sacred Heart Hosp, Div Cardiol, Seoul, South Korea
关键词
AMLODIPINE/VALSARTAN COMBINATION THERAPY; RECEPTOR ANTAGONIST; BLOOD-PRESSURE; PHARMACOKINETICS; TOLERABILITY; PREVENTION; VALSARTAN; OUTCOMES; TRIAL;
D O I
10.2165/11597410-000000000-00000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7 +/- 7.0 and 3.2 +/- 7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [1] Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with LosartanA Randomized, Double-Blind, Multicenter Study
    Bum-Kee Hong
    Chang Gyu Park
    Ki Sik Kim
    Myeong Ho Yoon
    Ho Joong Yoon
    Jeong Han Yoon
    Joo Young Yang
    Young Jin Choi
    Seung Yun Cho
    American Journal of Cardiovascular Drugs, 2012, 12 : 189 - 195
  • [2] Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study
    Hong, Soon Jun
    Jeong, Han Saem
    Han, Seung Hwan
    Chang, Ki Yuk
    Hong, Bum Kee
    Lee, Bong Ki
    Chae, Shung Chuii
    Kim, Woo Shik
    Park, Chang Gyu
    Heo, Jung Ho
    Lee, Seung Uk
    Kim, Young Dae
    Kim, Kee Sik
    Choi, Jung Hyun
    Kang, Hyun Jae
    Kim, Jae Joong
    Kang, Seok Min
    Choi, Young Jin
    Shin, Joon Han
    Chun, Kook Jin
    Shin, Dong Gu
    Park, Seong Hoon
    Kwan, Jun
    Choi, Yu Jeong
    Jeong, Myung Ho
    Chae, Jei Keon
    Kim, Dong Woon
    Cho, Jung Rae
    Han, Kyoo Rok
    Won, Kyung Heon
    Park, Sang Ho
    Lee, Sang Kon
    Kim, Sang Hoon
    Jung, Jina
    Kim, Cheol Ho
    CLINICAL THERAPEUTICS, 2017, 39 (10) : 2049 - 2060
  • [3] Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial
    Zhang, Shuyang
    Li, Ying
    Xu, Xin
    Xu, Rui
    Zhang, Linchao
    Wan, Xiaoqun
    Yao, Zhuhua
    Sun, Yuemin
    Liu, Yong
    Bin, Jianping
    Wang, Zhen
    Li, Shuren
    Yang, Ping
    Xu, Xiping
    Liang, Weidong
    Gao, Xiaohong
    Li, Xiaodong
    Jia, Min
    Ma, Guang
    Gu, Xiang
    Hong, Chang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [4] Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: A randomized, double blind, multicenter study
    Kim S.H.
    Ryu K.H.
    Lee N.-H.
    Kang J.-H.
    Kim W.-S.
    Park S.-W.
    Lee H.-Y.
    Kim J.-J.
    Ahn Y.-K.
    Suh S.Y.
    BMC Research Notes, 4 (1)
  • [5] Comparison of the Efficacy and Safety of Fixed-dose S-Amlodipine/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled with Telmisartan: A Randomized, Double-blind, Multicenter Study
    Park, Chang Gyu
    Tae Hun Ahn
    Cho, Eun Ju
    Kim, Won
    Kim, Hyung Seob
    Yang, Ju Yeong
    Ryu, Jae Geun
    Kim, Cheol Ho
    Hyeon, Min Soo
    Tak, Seung Je
    Im, Se Jung
    Ha, Jong Won
    Pyeon, Wook Beom
    Jae, Je Geon
    Han, Gyu Rok
    Doh, Jun Hyung
    Im, Sang Wook
    Lee, Myeong Muk
    CLINICAL THERAPEUTICS, 2016, 38 (10) : 2185 - 2194
  • [6] Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension
    Rakugi, Hiromi
    Tsuchihashi, Takuya
    Shimada, Kazuyuki
    Numaguchi, Hirotaka
    Nishida, Chisato
    Yamaguchi, Hiroya
    Shirakawa, Masayoshi
    Azuma, Kyoichi
    Fujita, Kenji P.
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2015, 37 (03) : 260 - 266
  • [7] Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers
    Yoon, Deok Yong
    Park, Sang-In
    Jung, Jin-A
    Kim, Yong-Il
    Jang, In-Jin
    Chung, Jae-Yong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 661 - 668
  • [8] A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE TRIPLE COMBINATION OF AMLODIPINE/LOSARTAN/ROSUVASTATIN IN PATIENTS WITH ESSENTIAL HYPERTENSION
    Lee, H.
    Park, S.
    JOURNAL OF HYPERTENSION, 2017, 35 : E193 - E193
  • [9] Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria
    Webb, Nicholas J. A.
    Lam, Chun
    Loeys, Tom
    Shahinfar, Shahnaz
    Strehlau, Juergen
    Wells, Thomas G.
    Santoro, Emanuela
    Manas, Denise
    Gleim, Gilbert W.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (03): : 417 - 424
  • [10] Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension - A double-blind randomized controlled study
    Martina, B
    Dieterle, T
    Weinbacher, M
    Battegay, E
    CARDIOLOGY, 1999, 92 (02) : 110 - 114